Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
Status:
Completed
Trial end date:
2016-03-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of
patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will
be enrolled into the dose-expansion cohort.